Pages that link to "Q80785300"
Jump to navigation
Jump to search
The following pages link to Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors (Q80785300):
Displaying 46 items.
- Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway (Q24647759) (← links)
- Safety of targeting tumor endothelial cell antigens (Q26748863) (← links)
- The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells (Q28474747) (← links)
- Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities (Q28751757) (← links)
- Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. (Q30483866) (← links)
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial (Q33417361) (← links)
- Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent (Q33546368) (← links)
- Integrin alpha(v)beta(3)-Targeted Cancer Therapy (Q33983773) (← links)
- Mesenchymal migration as a therapeutic target in glioblastoma (Q34002994) (← links)
- Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer (Q34128953) (← links)
- Integrins and bone metastasis: integrating tumor cell and stromal cell interactions (Q34441622) (← links)
- Integrin Targeted Therapeutics (Q34912684) (← links)
- Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part (Q35034608) (← links)
- Anti-angiogenic peptides for cancer therapeutics (Q35043016) (← links)
- Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models (Q35051626) (← links)
- Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential (Q35089514) (← links)
- Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium (Q35218871) (← links)
- Differential growth inhibition of cerebral metastases by anti-angiogenic compounds (Q35304863) (← links)
- Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation (Q35701298) (← links)
- Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β4 expression (Q36020955) (← links)
- Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis (Q36090830) (← links)
- Cancer treatment using peptides: current therapies and future prospects (Q36515785) (← links)
- Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors. (Q37052713) (← links)
- iACP: a sequence-based tool for identifying anticancer peptides (Q37086151) (← links)
- Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis (Q37426714) (← links)
- Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies (Q38032282) (← links)
- Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales (Q38130312) (← links)
- RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. (Q38161395) (← links)
- Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns (Q38269966) (← links)
- Inhibitory effects of novel integrin‐targeting peptides on angiogenesis activity in HUVEC cells in vitro (Q39540625) (← links)
- Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). (Q39767081) (← links)
- Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium (Q41814914) (← links)
- Integrins in tumor angiogenesis and lymphangiogenesis (Q42263292) (← links)
- MLACP: machine-learning-based prediction of anticancer peptides. (Q45944202) (← links)
- Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. (Q46079015) (← links)
- Cilengitide in glioblastoma: when did it fail? (Q48580387) (← links)
- In silico models for designing and discovering novel anticancer peptides (Q51150438) (← links)
- Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. (Q53714956) (← links)
- Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme (Q57141680) (← links)
- The functional role of integrins during intra- and extravasation within the metastatic cascade (Q61446515) (← links)
- ACP-DL: A Deep Learning Long Short-Term Memory Model to Predict Anticancer Peptides Using High-Efficiency Feature Representation. (Q64881052) (← links)
- Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle. (Q64983729) (← links)
- Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme (Q81615619) (← links)
- Filopodia and focal adhesions: An integrated system driving branching morphogenesis in neuronal pathfinding and angiogenesis (Q91334253) (← links)
- Pharmacologic inhibition of RGD-binding integrins ameliorates fibrosis and improves function following kidney injury (Q91853505) (← links)
- Emerging strategies to disrupt the central TGF-β axis in kidney fibrosis (Q91992554) (← links)